VIA
Virtus Investment Advisers Portfolio holdings
AUM
$296M
1-Year Return
31.42%
This Quarter Return
-1.68%
1 Year Return
+31.42%
3 Year Return
+126.24%
5 Year Return
–
10 Year Return
–
AUM
$368M
AUM Growth
+$240M
(+188%)
Cap. Flow
+$236M
Cap. Flow
% of AUM
64.25%
Top 10 Holdings %
Top 10 Hldgs %
25.49%
Holding
777
New
414
Increased
42
Reduced
13
Closed
237
Top Buys
| 1 |
Virtus Newfleet ABS/MBS ETF
VABS
|
$32.2M |
| 2 |
Virtus Newfleet Short Duration High Yield Bond ETF
VSHY
|
$24.6M |
| 3 |
Virtus SEIX Senior Loan ETF
SEIX
|
$19M |
| 4 |
SMC
Summit Midstream Corporation
SMC
|
$3.67M |
| 5 |
OCCI
OFS Credit Co
OCCI
|
$2.41M |
Top Sells
| 1 |
ICICI Bank
IBN
|
$3.75M |
| 2 |
Virtus Duff & Phelps Clean Energy ETF
VCLN
|
$2.74M |
| 3 |
Apple
AAPL
|
$2.06M |
| 4 |
Microsoft
MSFT
|
$2.02M |
| 5 |
Primoris Services
PRIM
|
$1.86M |
Sector Composition
| 1 | Financials | 24.48% |
| 2 | Healthcare | 11.95% |
| 3 | Technology | 8.6% |
| 4 | Industrials | 8.02% |
| 5 | Energy | 4.28% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
351
Xenon Pharmaceuticals
XENE
$3.02B
| $140K | 0.04% |
+4,161
| New | +$140K |
|
352
CEMIG Preferred Shares
CIG
$5.84B
| $140K | 0.04% |
+79,312
| New | +$140K |
|
353
CG Oncology
CGON
$2.52B
| $139K | 0.04% |
+5,686
| New | +$139K |
|
354
Cosan
CSAN
$2.47B
| $139K | 0.04% |
+26,672
| New | +$139K |
|
355
Apogee Therapeutics
APGE
$2.26B
| $138K | 0.04% |
+3,701
| New | +$138K |
|
|
LENZ
356
LENZ Therapeutics
LENZ
$1.2B
| $137K | 0.04% |
+5,334
| New | +$137K |
|
357
MindMed
MNMD
$702M
| $137K | 0.04% |
+23,388
| New | +$137K |
|
358
Kimbell Royalty Partners
KRP
$1.25B
| $136K | 0.04% |
+9,727
| New | +$136K |
|
359
Kimco Realty
KIM
$15.4B
| $136K | 0.04% |
+6,400
| New | +$136K |
|
360
Savara
SVRA
$643M
| $136K | 0.04% |
+49,006
| New | +$136K |
|
361
Pharvaris
PHVS
$1.48B
| $136K | 0.04% |
+8,636
| New | +$136K |
|
362
Sana Biotechnology
SANA
$752M
| $135K | 0.04% |
+80,467
| New | +$135K |
|
363
Regenxbio
RGNX
$490M
| $135K | 0.04% |
+18,830
| New | +$135K |
|
364
Nuvalent
NUVL
$5.83B
| $134K | 0.04% |
+1,890
| New | +$134K |
|
365
NewAmsterdam Pharma
NAMS
$3.04B
| $134K | 0.04% |
+6,543
| New | +$134K |
|
366
Kite Realty
KRG
$5.11B
| $133K | 0.04% |
+5,967
| New | +$133K |
|
|
PBT
367
Permian Basin Royalty Trust
PBT
$838M
| $133K | 0.04% |
+13,420
| New | +$133K |
|
368
GeoPark
GPRK
$326M
| $132K | 0.04% |
+16,382
| New | +$132K |
|
369
Urban Edge Properties
UE
$2.67B
| $132K | 0.04% |
6,949
-7,051
| -50% | -$134K |
|
370
Celcuity
CELC
$2.36B
| $132K | 0.04% |
+13,020
| New | +$132K |
|
371
Cytokinetics
CYTK
$6.34B
| $131K | 0.04% |
+3,270
| New | +$131K |
|
372
Replimune Group
REPL
$494M
| $131K | 0.04% |
+13,434
| New | +$131K |
|
373
California Resources
CRC
$4.1B
| $130K | 0.04% |
+2,965
| New | +$130K |
|
374
Revolution Medicines
RVMD
$7.57B
| $129K | 0.04% |
+3,652
| New | +$129K |
|
375
Arcellx
ACLX
$4.03B
| $129K | 0.04% |
+1,968
| New | +$129K |
|